Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1989 Oct;28(4):415-20.
doi: 10.1111/j.1365-2125.1989.tb03521.x.

Lisinopril dose-response relationship in essential hypertension

H J Gomez  1 , V J Cirillo, J A Sromovsky, E S Otterbein, W C Shaw, J E Rush, S G Chrysant, A H Gradman, A S Leon, E P MacCarthy, et al.
Affiliations
Clinical Trial

Lisinopril dose-response relationship in essential hypertension

H J Gomez et al. Br J Clin Pharmacol. 1989 Oct.

Abstract

1. This was a multicentre, double-blind, parallel study in 216 patients with mild to moderate (supine diastolic blood pressure = 95-115 mm Hg) essential hypertension. 2. After a 4-week placebo washout, patients were randomized to placebo or lisinopril 1.25, 5.20 or 80 mg once daily for 6 consecutive weeks. Supine and erect blood pressure was measured 24 h postdose at the end of weeks -2, 0, 2, 4, and 6. 3. There was a linear dose-response relationship for both supine and erect blood pressure. Diastolic blood pressure reductions in the lisinopril 20 and 80 mg day-1 groups were significantly greater than in the placebo or lisinopril 1.25 and 5 mg day-1 groups. 4. Lisinopril, at doses up to 80 mg day-1, was well tolerated.

PubMed Disclaimer

References

    1. Br J Clin Pharmacol. 1982 Sep;14(3):357-62 - PubMed
    1. Br J Clin Pharmacol. 1985 May;19(5):605-11 - PubMed
    1. Stat Med. 1986 Sep-Oct;5(5):449-57 - PubMed
    1. J Cardiovasc Pharmacol. 1987;9 Suppl 3:S27-34 - PubMed
    1. J Cardiovasc Pharmacol. 1987;9 Suppl 3:S36-42 - PubMed

Publication types

MeSH terms